Trevi Therapeutics’ (TRVI) “Buy” Rating Reiterated at D. Boral Capital

D. Boral Capital reiterated their buy rating on shares of Trevi Therapeutics (NASDAQ:TRVI) in a report published on Thursday,Benzinga reports. D. Boral Capital currently has a $19.00 target price on the stock.

Other research analysts also recently issued research reports about the company. Stifel Nicolaus lifted their price target on Trevi Therapeutics from $15.00 to $18.00 and gave the stock a “buy” rating in a research note on Friday, December 19th. Oppenheimer raised their target price on shares of Trevi Therapeutics from $23.00 to $24.00 and gave the company an “outperform” rating in a report on Friday, November 14th. B. Riley raised shares of Trevi Therapeutics to a “strong-buy” rating in a report on Monday, November 17th. Leerink Partners increased their price target on shares of Trevi Therapeutics from $13.00 to $16.00 and gave the company an “outperform” rating in a research report on Wednesday, November 19th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Trevi Therapeutics in a research note on Wednesday, October 8th. Two research analysts have rated the stock with a Strong Buy rating, eight have issued a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Buy” and an average price target of $21.10.

Trevi Therapeutics Trading Down 0.3%

NASDAQ:TRVI opened at $11.18 on Thursday. The firm has a market cap of $1.43 billion, a P/E ratio of -30.22 and a beta of 0.91. The stock has a 50 day moving average of $12.19 and a two-hundred day moving average of $9.53. Trevi Therapeutics has a 12 month low of $3.47 and a 12 month high of $14.39.

Trevi Therapeutics (NASDAQ:TRVI) last released its quarterly earnings data on Thursday, November 13th. The company reported ($0.08) earnings per share for the quarter, beating the consensus estimate of ($0.10) by $0.02. On average, research analysts forecast that Trevi Therapeutics will post -0.49 earnings per share for the current year.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the business. SG Americas Securities LLC boosted its holdings in shares of Trevi Therapeutics by 93.0% during the fourth quarter. SG Americas Securities LLC now owns 124,562 shares of the company’s stock worth $1,560,000 after purchasing an additional 60,017 shares during the last quarter. Diversified Trust Co. grew its holdings in Trevi Therapeutics by 14.6% in the 4th quarter. Diversified Trust Co. now owns 20,984 shares of the company’s stock valued at $263,000 after buying an additional 2,675 shares during the period. Vivo Capital LLC increased its stake in shares of Trevi Therapeutics by 13.5% during the 3rd quarter. Vivo Capital LLC now owns 5,094,668 shares of the company’s stock valued at $46,616,000 after acquiring an additional 606,765 shares during the last quarter. Velan Capital Investment Management LP purchased a new position in shares of Trevi Therapeutics during the 3rd quarter worth about $1,876,000. Finally, Qube Research & Technologies Ltd boosted its position in shares of Trevi Therapeutics by 45.5% in the third quarter. Qube Research & Technologies Ltd now owns 651,679 shares of the company’s stock worth $5,963,000 after acquiring an additional 203,827 shares during the last quarter. 95.76% of the stock is currently owned by institutional investors and hedge funds.

About Trevi Therapeutics

Trevi Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the development of novel non-opioid therapies for the management of chronic and acute pain. The company leverages proprietary drug delivery platforms and targeted molecular approaches to address high unmet needs in cancer-related pain, chemotherapy-induced neuropathy and other severe pain conditions.

Its lead product candidate is a proprietary formulation of tetrodotoxin (TTX), a sodium-channel blocking agent being evaluated in early-stage clinical trials for moderate-to-severe pain associated with advanced cancer and peripheral neuropathy.